Nivolumab
8 ASCO studies your colleagues are still talking about
Nearly 7,000 abstracts had been submitted for presentation at this year’s ASCO Annual Meeting.
Addition of bacterial product to kidney cancer regimen may delay disease progression
CHICAGO — The addition of CBM588 to immune checkpoint inhibitor-based therapy significantly increased PFS and response rates with no impact on stool microbiome diversity among a small cohort of patients with metastatic renal cell carcinoma.
Novel AhR inhibitor shows tolerability, activity in advanced solid tumors
CHICAGO — A novel oral aryl hydrocarbon receptor inhibitor appeared well tolerated and safe among a small cohort of patients with advanced solid tumors, according to phase 1 study results presented at ASCO Annual Meeting.
Biomarkers predict benefit of adjuvant nivolumab in resected melanoma
CHICAGO — Several biomarkers predicted outcomes with adjuvant nivolumab vs. placebo for patients with resected stage IIB or IIC melanoma, according to study results presented at ASCO Annual Meeting.
Nivolumab regimen ‘a huge advance’ in treatment of classical Hodgkin lymphoma
CHICAGO — The addition of nivolumab vs. brentuximab vedotin to AVD chemotherapy significantly reduced the risk for disease progression and disease-related death among adults with previously untreated advanced classic Hodgkin lymphoma.
Some patients with stage III melanoma can avoid surgery after neoadjuvant immunotherapy
CHICAGO — Tumor lymph node dissection likely can be omitted for patients with melanoma who achieve major pathologic response after neoadjuvant immune checkpoint blockade, according to study results presented at ASCO Annual Meeting.
Sitravatinib plus nivolumab fails to extend survival in phase 3 lung cancer study
The addition of sitravatinib to nivolumab failed to extend OS, when compared with docetaxel, among certain patients with nonsquamous non-small cell lung cancer, according to topline data from the agent’s manufacturer.
Novel immunotherapy approach benefits patients with melanoma, leptomeningeal disease
Concurrent intrathecal and IV nivolumab appeared safe and showed potential efficacy among a small cohort of patients with melanoma and leptomeningeal disease, according to results of a phase 1/1b study published in Nature Medicine.
Vitamin D supplementation may improve immunotherapy response in advanced melanoma
Maintenance of normal vitamin D levels during anti-PD-1 immunotherapy should be standard procedure for patients with advanced melanoma to allow for better treatment outcomes, according to a report in Cancer.
Nivolumab plus chemotherapy confers sustained benefit for patients with NSCLC
Neoadjuvant nivolumab plus platinum-based chemotherapy conferred sustained clinical benefit for patients with resectable non-small cell lung cancer, 3-year follow-up results of the phase 3 CheckMate -816 trial showed.